BUZZ-Humana shares rise on improved “Federal Medicare Advantage Plan” ratings
路透社2026/10/09 09:11October 9 – Humana Inc (HUM.N) shares surged 14.4% in pre-market trading to $443. According to U.S. government data, 95% of HUM members participating in the “Medicare Advantage Plan” were rated four stars or higher for 2027. Higher star ratings are crucial for insurance companies, as they result in government bonuses and can boost plan enrollment. Oppenheimer analysts estimate the improved ratings could add $3.6 billion in revenue for the company. In contrast, according to Oppenheimer, competitors UnitedHealth Group (UNH.N) and CVS Health (CVS.N) saw their average ratings fall by 15% from last year, while Elevance (ELV.N) and Centene (CNC.N) also experienced declines. As of the previous trading session, HUM had gained 51% year-to-date, while UNH, CVS, and ELV posted gains between 10% and 14.4%, and CNC surged 57%.
October 9 - ** Humana Inc HUM.N shares soared 14.4% in pre-market trading to $443
** According to U.S. government data, 95% of HUM members (link) enrolled in the "Medicare Advantage" plan received a four-star rating or higher for the 2027 assessment year
** Higher star ratings are crucial for insurance companies, as they bring government bonuses and can boost plan enrollment
** Oppenheimer analysts estimate that the improved rating could generate an additional $3.6 billion in revenue for the company
** By contrast, according to Oppenheimer, average ratings for competitors UnitedHealth Group UNH.N and CVS Health CVS.N declined by 15% compared to last year, while ratings for Elevance (ELV.N) and Centene (CNC.N) also decreased
** As of the previous trading session's close, HUM has risen 51% so far this year, while UNH, CVS, and ELV rose between 10% and 14.4%, and CNC surged 57%
(To facilitate non-English speakers, Reuters provides its reports automatically translated into several other languages. As automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of automated translation texts and provides them solely for the reader’s convenience. Reuters assumes no responsibility for any damage or loss caused by the use of automated translation functions.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
